BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 1999

View Archived Issues

AstraZeneca takes an ambitious approach to drug R&D

Read More

HIV-VAC's AIDS vaccine progressing in clinical trials in Russia

Read More

New class of antidiabetic agents under study at Novo Nordisk

Read More

Boehringer Ingelheim assumes full responsibility for continued development of novel antitumor agent

Read More

Hypoxanthine derivatives from NeoTherapeutics useful for depression, obesity, etc.

Read More

Mallinckrodt's MRI contrast agent approved for marketing in U.S.

Read More

ImmunoGen's lead tumor-activated prodrug enters the clinic

Read More

"Inactive" pharmaceutical excipient demonstrates potent anti-HSV activity in vitro and in vivo

Read More

Ribozyme to form joint venture with Elan for breast cancer therapeutic

Read More

Water-soluble mesilate salt form of known antitumor agent prepared at Pfizer

Read More

Antiproliferative agents derived from vegetable oil in development at PharmaScience

Read More

Medivir investigates new treatments for hepatitis B

Read More

A6/cyclophosphamide combination to be studied as antimetastatic therapy

Read More

HU-308: a potent and specific agonist at the peripheral cannabinoid receptor

Read More

AHP denies rumors of merger talks with P&U

Read More

Zambon initiates phase II trial of Sheffield's MSI albuterol

Read More

Vion's TAPET administered to first patients intratumorally in phase I trial

Read More

HGF gene therapy for acute GVHD: studies in mice

Read More

AEterna presents promising phase I data for AE-941 in AMD

Read More

KRN-7000-stimulated human cells effective in vitro against melanoma cell lines

Read More

Cypress Bioscience and Medexus enter agreement for Prosorba Column in Canada

Read More

New chikungunya virus vaccine safe and highly immunogenic in humans

Read More

Recombinant HEV vaccine: safety and immunogenicity in monkeys and humans

Read More

PPL Therapeutics announces promising preliminary data from AAT deficiency trial

Read More

Lorus Therapeutics cleared to initiate clinical trials of GTI-2040

Read More

Merck KGaA finalizes Theramex acquisition

Read More

Potent new anticonvulsants emerge from China

Read More

Versicor achieves milestone in antibacterial collaboration with Novartis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing